TScan Therapeutics (NASDAQ:TCRX) just reported results for the first quarter of 2024.
- TScan Therapeutics reported earnings per share of -32 cents. This was below the analyst estimate for EPS of -25 cents.
- The company reported revenue of $566,000.
- This was 85.74% worse than the analyst estimate for revenue of $3.97 million.